In a filing, Checkpoint Therapeutics Inc. revealed its CEO, President and Director Oliviero James F III unloaded Company’s shares for reported $16650.0 on Jun 23. In the deal valued at $1.11 per share,15,000 shares were sold. As a result of this transaction, Oliviero James F III now holds 2,562,003 shares worth roughly $ 1.77 million.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, Oliviero James F III sold 12,000 shares, generating $13,080 in total proceeds. Upon selling the shares at $1.09, the CEO, President and Director now owns 2,577,003 shares.
Before that, Oliviero James F III sold 21,000 shares. Checkpoint Therapeutics Inc. shares valued at $22,890 were divested by the CEO, President and Director at a price of $1.09 per share. As a result of the transaction, Oliviero James F III now holds 2,589,003 shares, worth roughly $1.79 million.
PT values the company’s stock at a premium of 90.14 to its Monday closing price. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in early June with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering CKPT with “an Overweight” recommendation on January 20, 2021. Lake Street started covering the stock on May 29, 2019. It rated CKPT as “a Buy”.
Price Performance Review of CKPT
On Monday, Checkpoint Therapeutics Inc. [NASDAQ:CKPT] saw its stock fall -23.99% to $0.69. On the same session, the stock had its day’s lowest price of $0.502, but rose to a high of $0.8808. Over the last five days, the stock has lost -31.36%. Checkpoint Therapeutics Inc. shares have fallen nearly -77.93% since the year began. Nevertheless, the stocks have fallen -83.85% over the past one year. While a 52-week high of $4.64 was reached on 01/04/22, a 52-week low of $0.86 was recorded on 11/07/22. SMA at 50 days reached $1.0829, while 200 days put it at $1.3900. A total of 2.18 million shares were traded, compared to the trading of 90100.0 shares in the previous session.
Levels Of Support And Resistance For CKPT Stock
The 24-hour chart illustrates a support level at 0.4987, which if violated will result in even more drops to 0.3109. On the upside, there is a resistance level at 0.8775. A further resistance level may holdings at 1.0685. The Relative Strength Index (RSI) on the 14-day chart is 24.43, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0844, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.40%. Stochastics %K at 40.25% indicates the stock is a holding.
How much short interest is there in Checkpoint Therapeutics Inc.?
A steep rise in short interest was recorded in Checkpoint Therapeutics Inc. stocks on Jul 14, 2022, dropping by -0.12 million shares to a total of 3.13 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 3.25 million shares. There was a decline of -3.83%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 4.48% of the overall stock float, the days-to-cover ratio (short ratio) fell to 7.55.
Checkpoint Therapeutics Inc. [CKPT] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 2,997,460 shares, or roughly 3.51% of the outstanding CKPT shares. Additionally, Jess S. Morgan & Co., Inc. increased 66.59% of its stake after which the total value it holdings stand at $1,970,482, while BlackRock Fund Advisors added 3.93% of its stake to hold $0.99 million in the firm. Over the last quarter, Millennium Management LLC sold -294,446 shares of Checkpoint Therapeutics Inc., while Renaissance Technologies LLC sold -168,645 shares. At present, Geode Capital Management LLC is holding 668,784 shares valued at $0.7 million. Norges Bank Investment Management owned 268,500 shares of the company at the time of its most recent 13F filing, worth $0.28 million.
According to FactSet, Checkpoint Therapeutics Inc.’s share price will average $18.50 in the next year, based on opinions of analysts polled by the firm. This is up nearly 2177.78 percent from its previous closing price of $0.90. Analysts expect Checkpoint Therapeutics Inc. stock to reach the higher price of $26.00, while the lowest price estimate is $7.00. However, 4 analysts have rated CKPT stock as a Buy in their predictions for 2022. The most recent change occurred on December 08, 2017 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $11 price target.